Terms: = Prostate cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF
1436 results:
1. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G; Malek R; Mannuel H; Hussain A
Curr Opin Oncol; 2024 May; 36(3):195-201. PubMed ID: 38573209
[TBL] [Abstract] [Full Text] [Related]
2. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract] [Full Text] [Related]
3. Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.
Einstein DJ; Aragon-Ching JB; Karzai F; Madan RA
Curr Opin Oncol; 2024 May; 36(3):164-168. PubMed ID: 38573205
[TBL] [Abstract] [Full Text] [Related]
4. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment.
He Y; Yu Q; Ma X; Lv D; Wang H; Qiu W; Chen XF; Jiao Y; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118075. PubMed ID: 38513779
[TBL] [Abstract] [Full Text] [Related]
5. Printing of 3D biomimetic structures for the study of bone metastasis: A review.
Khanmohammadi M; Volpi M; Walejewska E; Olszewska A; Swieszkowski W
Acta Biomater; 2024 Apr; 178():24-40. PubMed ID: 38458512
[TBL] [Abstract] [Full Text] [Related]
6. Optimal systemic therapy in men with low-volume prostate cancer.
Saxena A; Andrews J; Bryce AH; Riaz IB
Curr Opin Urol; 2024 May; 34(3):183-197. PubMed ID: 38445371
[TBL] [Abstract] [Full Text] [Related]
7. Metastasis-directed therapy in oligometastatic prostate cancer.
Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
[TBL] [Abstract] [Full Text] [Related]
8. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.
Paindelli C; Parietti V; Barrios S; Shepherd P; Pan T; Wang WL; Satcher RL; Logothetis CJ; Navone N; Campbell MT; Mikos AG; Dondossola E
Acta Biomater; 2024 Apr; 178():83-92. PubMed ID: 38387748
[TBL] [Abstract] [Full Text] [Related]
9. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in prostate cancer.
Sentana-Lledo D; Morgans AK
Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
[TBL] [Abstract] [Full Text] [Related]
10. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
Chen H; Dong K; Ding J; Xia J; Qu F; Lan F; Liao H; Qian Y; Huang J; Xu Z; Gu Z; Shi B; Yu M; Cui X; Yu Y
Cancer Lett; 2024 Apr; 587():216725. PubMed ID: 38364963
[TBL] [Abstract] [Full Text] [Related]
11. Stereotactic ablative radiation therapy in metastatic prostate cancer.
Bazyar S; Mannuel H; Tran PT
Curr Opin Oncol; 2024 May; 36(3):180-185. PubMed ID: 38362949
[TBL] [Abstract] [Full Text] [Related]
12. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract] [Full Text] [Related]
13. The Dairy and cancer Controversy: Milking the Evidence.
Scialo TE; Pace CM; Abrams DI
Curr Oncol Rep; 2024 Mar; 26(3):191-199. PubMed ID: 38289521
[TBL] [Abstract] [Full Text] [Related]
14. Germline Mutations and Ancestry in prostate cancer.
Bataba E; Babcock K; Isensee KA; Eldhose B; Kohaar I; Chesnut GT; Dobi A
Curr Oncol Rep; 2024 Feb; 26(2):175-180. PubMed ID: 38265515
[TBL] [Abstract] [Full Text] [Related]
15. The Role of Osteocytes in Pre-metastatic Niche Formation.
Briggs EN; Lynch ME
Curr Osteoporos Rep; 2024 Feb; 22(1):105-114. PubMed ID: 38198034
[TBL] [Abstract] [Full Text] [Related]
16. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
[TBL] [Abstract] [Full Text] [Related]
17. cancer survivor late-effects, chronic health problems after cancer treatment: what's the evidence from population and registry data and where are the gaps?
Faithfull S; Greenfield D
Curr Opin Support Palliat Care; 2024 Mar; 18(1):55-64. PubMed ID: 38170192
[TBL] [Abstract] [Full Text] [Related]
18. prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Soto ÁJ; Uemura H; Ye DW; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
Future Oncol; 2024 Mar; 20(10):563-578. PubMed ID: 38126311
[TBL] [Abstract] [Full Text] [Related]
19. Assessment of prostate and Bladder cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review.
Bazarkin A; Morozov A; Androsov A; Fajkovic H; Rivas JG; Singla N; Koroleva S; Teoh JY; Zvyagin AV; Shariat SF; Somani B; Enikeev D
Curr Urol Rep; 2024 Jan; 25(1):19-35. PubMed ID: 38099997
[TBL] [Abstract] [Full Text] [Related]
20. UPLC-Q-TOF-MS profiling of Viola stocksii Boiss. and evaluation of aphrodisiac potential and risk factors associated with erectile dysfunction.
Basit A; Khan KUR; Rahman AU; Khan M; Ahmad T; Arafat M; Khan KU; Nalinbenjapun S; Sripetthong S; Ovatlarnporn C
J Ethnopharmacol; 2024 Mar; 321():117477. PubMed ID: 38007166
[TBL] [Abstract] [Full Text] [Related]
[Next]
